

## Neomycin Sulfate and Dexamethasone Sodium Phosphate Ophthalmic Ointment

### DEFINITION

Neomycin Sulfate and Dexamethasone Sodium Phosphate Ophthalmic Ointment is a sterile ointment containing Neomycin Sulfate and Dexamethasone Sodium Phosphate. It contains the equivalent of NLT 90.0% and NMT 135.0% of the labeled amount of neomycin, and the equivalent of NLT 90.0% and NMT 110.0% of the labeled amount of dexamethasone phosphate ( $C_{22}H_{30}FO_8P$ ).

[NOTE—Where Neomycin Sulfate and Dexamethasone Sodium Phosphate Ophthalmic Ointment is prescribed without reference to the quantity of neomycin or dexamethasone phosphate contained therein, a product containing 3.5 mg of neomycin and 0.5 mg of dexamethasone phosphate per g shall be dispensed.]

### IDENTIFICATION

- **A. THIN-LAYER CHROMATOGRAPHIC IDENTIFICATION TEST** (201BNP): Meets the requirements

### Delete the following:

- **B. THIN-LAYER CHROMATOGRAPHY**

**Buffer:** 3.1 g/L of boric acid, 203 mg/L of magnesium chloride, and 860 mg/L of sodium hydroxide in water. The pH of this solution is 9.0.

**Solution A:** 1 mg/mL of alkaline phosphatase enzyme in Buffer

**Standard solution:** 300  $\mu$ g/mL of USP Dexamethasone RS in methylene chloride

**Sample stock solution:** Use the *Sample solution* prepared as directed in the *Assay for Dexamethasone Phosphate*.

**Sample solution:** Transfer 5 mL of the *Solution A* to a glass-stoppered, 50-mL tube containing 5 mL of *Sample stock solution*, incubate at 37° for 45 min, then add 25 mL of methylene chloride, and shake for 2 min. Evaporate 15 mL of the methylene chloride extract on a steam bath to dryness, and dissolve the residue in 1 mL of methylene chloride.

#### Chromatographic system

(See *Chromatography* (621), *Thin-Layer Chromatography*.)

**Adsorbent:** 0.25-mm layer of chromatographic silica gel

**Application volume:** 5  $\mu$ L

**Developing solvent system:** Chloroform, acetone, and water (50:50:1)

**Spray reagent:** Dilute sulfuric acid (1 in 2)

#### Analysis

**Samples:** *Standard solution* and *Sample solution*  
Apply the *Standard solution* and *Sample solution* to the plate and allow the spots to dry. Develop the chromatogram using the *Developing solvent system* in a tank completely lined with filter paper, until the solvent front has moved about three-fourths of the length of the plate. Remove the plate from the developing tank, mark the solvent front, and allow the spots to dry. Spray the plate with *Spray reagent*, and heat at 105° until brown or black spots appear.

**Acceptance criteria:** The  $R_f$  value of the principal spot from the *Sample solution* corresponds to that from the *Standard solution*. (IRA 1-May-2015)

### Add the following:

- **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the *Assay for Dexamethasone Phosphate*. (IRA 1-May-2015)

### ASSAY

- **NEOMYCIN**

(See *Antibiotics—Microbial Assays* (81).)

**Sample solution:** Shake a weighed portion of Ophthalmic Ointment in a separator with about 50 mL of ether, and extract with four 20-mL portions of Buffer B.3. Combine the aqueous extracts, and dilute with Buffer B.3 to a suitable volume.

**Analysis:** Proceed as directed in the chapter. Dilute the *Sample solution* with Buffer B.3 to obtain a *Test Dilution* having a neomycin concentration that is nominally equivalent to the median level of the standard.

**Acceptance criteria:** 90.0%–135.0%

### Change to read:

- **DEXAMETHASONE PHOSPHATE**

**Buffer:** 6.9 g/L of monobasic sodium phosphate

**Mobile phase:** Methanol and Buffer (52:48)

**Diluent:** Dissolve 0.29 g of dibasic sodium phosphate in 450 mL of water, and add 550 mL of alcohol.

**Standard solution:** 33  $\mu$ g/mL of USP Dexamethasone Sodium Phosphate RS. (IRA 1-May-2015) in *Diluent*. Prepare this solution freshly.

**Sample solution:** Nominally 30  $\mu$ g/mL of dexamethasone phosphate, prepared as follows. Transfer a portion of Ophthalmic Ointment containing nominally 3 mg of dexamethasone phosphate to a suitable beaker. Add 65 mL of *Diluent*, and heat just to boiling. Pour the contents of the beaker into a separator containing 45 mL of isooctane. After shaking for 1 min, decant the lower layer into a 100-mL volumetric flask. Rinse the beaker with two 15-mL portions of *Diluent*, extracting the remaining isooctane in the separator with each portion, and decanting the lower layer from each extraction into the 100-mL volumetric flask. Dilute with *Diluent* to volume, and mix. Pass through a suitable filter.

#### Chromatographic system

(See *Chromatography* (621), *System Suitability*.)

**Mode:** LC

**Detector:** UV 254 nm

**Column:** 3.9-mm  $\times$  30-cm; 10- $\mu$ m. (IRA 1-May-2015) packing L1

**Flow rate:** 1.5 mL/min

**Injection volume:** 20  $\mu$ L

#### System suitability

**Sample:** *Standard solution*

[NOTE—The retention time for dexamethasone phosphate is about 8.5 min.]

#### Suitability requirements

**Relative standard deviation:** NMT 1.5%

#### Analysis

**Samples:** *Standard solution* and *Sample solution*  
Calculate the percentage of the labeled amount of dexamethasone phosphate ( $C_{22}H_{30}FO_8P$ ) in the portion of Ophthalmic Ointment taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (M_{r1}/M_{r2}) \times 100 \quad (\text{IRA 1-May-2015})$$

$r_U$  = peak response from the *Sample solution*

$r_S$  = peak response from the *Standard solution*

## 2 Neomycin

$C_s$  = concentration of • USP Dexamethasone Sodium Phosphate RS • (IRA 1-May-2015) in the *Standard solution* ( $\mu\text{g/mL}$ )

$C_u$  = nominal concentration of dexamethasone phosphate in the *Sample solution* ( $\mu\text{g/mL}$ )

• = molecular weight of dexamethasone phosphate, 472.44

$M_{r1}$   $M_{r2}$  = molecular weight of dexamethasone sodium phosphate, 516.40 • (IRA 1-May-2015)

Acceptance criteria: 90.0%–110.0%

### PERFORMANCE TESTS

- **MINIMUM FILL** (755): Meets the requirements

### SPECIFIC TESTS

- **WATER DETERMINATION**, *Method I* (921)  
Analysis: Use 20 mL of a mixture of toluene and methanol (7:3) in place of methanol in the titration vessel.  
Acceptance criteria: NMT 1.0%
- **STERILITY TESTS** (71): Meets the requirements
- **METAL PARTICLES IN OPHTHALMIC OINTMENTS** (751): Meets the requirements

### ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in collapsible ophthalmic ointment tubes.

### Change to read:

- **USP REFERENCE STANDARDS** (11)

- USP Dexamethasone Sodium Phosphate RS

- (IRA 1-May-2015)

- USP Neomycin Sulfate RS